Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Lymphedema-cerebral arteriovenous anomaly syndrome is characterized by the variable association of a cerebrovascular malformation, foot lymphoedema and primary pulmonary hypertension. It has been described in a woman and four of her children.
Features include: Abnormal cerebral vascular morphology, High blood pressure in lung arteries (pulmonary arterial hypertension), and Lymphedema.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 1 | Abnormal cerebral vascular morphology |
Biomarker and diagnostic research for lymphedema-cerebral arteriovenous anomaly syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for lymphedema-cerebral arteriovenous anomaly syndrome.
156 publications have been identified in PubMed for lymphedema-cerebral arteriovenous anomaly syndrome. Research spans Case Report / Case Series (56%), Review / Meta-Analysis (28%), and Epidemiology / Natural History (6%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 88 | 56% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 12:52 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 |
High blood pressure in lung arteries (pulmonary arterial hypertension) |
Lungs and breathing | 1 | High blood pressure in lung arteries (pulmonary arterial hypertension) |
Skin | 1 | Lymphedema |
Research summaries |
43 |
28% |
Disease patterns and progression | 9 | 6% |
Other research | 7 | 4% |
Laboratory research | 5 | 3% |
Testing and diagnosis research | 2 | 1% |
Clinical study results | 2 | 1% |
Khauli S (2026). [PMID: 30521255](https://pubmed.ncbi.nlm.nih.gov/30521255/). *Unknown Journal*. [Other]
Mantry V (2026). [PMID: 41526065](https://pubmed.ncbi.nlm.nih.gov/41526065/). *BMJ Case Rep*. [Case Report / Case Series]
Watanabe T (2026). [PMID: 41550620](https://pubmed.ncbi.nlm.nih.gov/41550620/). *J Cardiol Cases*. [Case Report / Case Series]
Pakhathirathien P (2026). [PMID: 41224725](https://pubmed.ncbi.nlm.nih.gov/41224725/). *Hum Mol Genet*. [Basic Science / Preclinical]
Malenica M (2026). [PMID: 41520207](https://pubmed.ncbi.nlm.nih.gov/41520207/). *Croat Med J*. [Case Report / Case Series]
Elmali A (2026). [PMID: 37078175](https://pubmed.ncbi.nlm.nih.gov/37078175/). *J Oncol Pharm Pract*. [Case Report / Case Series]
Alobaidy AAA (2026). [PMID: 42103339](https://pubmed.ncbi.nlm.nih.gov/42103339/). *BMJ Case Rep*. [Case Report / Case Series]
Lu JT (2026). [PMID: 41147663](https://pubmed.ncbi.nlm.nih.gov/41147663/). *J Eur Acad Dermatol Venereol*. [Review / Meta-Analysis]
Danyalian A (2026). [PMID: 32809531](https://pubmed.ncbi.nlm.nih.gov/32809531/). *Unknown Journal*. [Other]
Morin G (2026). [PMID: 41272322](https://pubmed.ncbi.nlm.nih.gov/41272322/). *EMBO Mol Med*. [Review / Meta-Analysis]